CN
CN
BioNova Receives Investigational New Drug Clearance for BN301 for the Treatment of Hematologic Malignancies in China
September 05, 2022

SHANGHAI, China, September. 5, 2022 - BioNova today announced that Center of Drug Evaluation (CDE) of National Medical Products Administration (NMPA) had approved its investigational new drug (IND) application for BN301 (STRO-001) to conduct clinical trials in patients with hematologic malignancies in China.